Lupin Announces Approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States

MUMBAI, India and NAPLES, Fla., April 8, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA)...